GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA
Provider: View Press Release Type: Link Title: GSK unveils latest research advances demonstrating strength of its portfolio and pipeline at ASCO and EHA | GSK Description: GSK plc will present 25 abstracts at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
GSK announces Dr Vishal Sikka to join the Board as Non-Executive Director
Provider: View Press Release Type: Link Title: GSK announces Dr Vishal Sikka to join the Board as Non-Executive Director | GSK Description: GSK has announced that Dr Vishal Sikka, founder and CEO of Vianai Systems, will join the Board of the Company as a Non-Executive Director.
SK bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea
SK bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea
Provider: View Press Release Type: Link Title: SK bioscience and GSK’s adjuvanted COVID-19 vaccine candidate meets coprimary objectives in a phase III study; Biologics License Application submitted for SKYCovione™(GBP510/GSK adjuvant) in South Korea | GSK Description: SK submits license application to MFDS to support vaccine sovereignty in South Korea
US Food and Drug Administration accepts New Drug Application for daprodustat
Provider: View Press Release Type: Link Title: US Food and Drug Administration accepts New Drug Application for daprodustat | GSK Description: US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat
GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn
Provider: View Press Release Type: Link Title: GSK reaches agreement to acquire late-stage biopharmaceutical company Sierra Oncology for $1.9bn | GSK Description: Myelofibrosis is a fatal cancer of the bone marrow impacting the normal production of blood cells.
